Published in Clin Diagn Lab Immunol on November 01, 1999
Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J Biol Chem (2002) 2.59
Regulation of Candida albicans morphogenesis by fatty acid metabolites. Infect Immun (2004) 1.24
Immunological evaluation of Lactobacillus casei Zhang: a newly isolated strain from koumiss in Inner Mongolia, China. BMC Immunol (2008) 1.00
Lactobacillus casei reduces the inflammatory joint damage associated with collagen-induced arthritis (CIA) by reducing the pro-inflammatory cytokines: Lactobacillus casei: COX-2 inhibitor. J Clin Immunol (2010) 0.99
Anti-inflammatory activity of lactobacillus on carrageenan-induced paw edema in male wistar rats. Int J Inflam (2012) 0.93
Evaluation of immunomodulatory effects of lactic acid bacteria in turbot (Scophthalmus maximus). Clin Diagn Lab Immunol (2002) 0.85
Wild blueberries (Vaccinium myrtillus) alleviate inflammation and hypertension associated with developing obesity in mice fed with a high-fat diet. PLoS One (2014) 0.81
Immunostimulatory Effects Triggered by Enterococcus faecalis CECT7121 Probiotic Strain Involve Activation of Dendritic Cells and Interferon-Gamma Production. PLoS One (2015) 0.76
Development of probiotic tablets using microparticles: viability studies and stability studies. AAPS PharmSciTech (2012) 0.75
Goat Milk Yoghurt by Using Lacto-B Culture Modulates the Production of Tumor Necrosis Factor-Alpha and Interleukin-10 in Malnourished Rats. Korean J Food Sci Anim Resour (2014) 0.75
Functional food science and gastrointestinal physiology and function. Br J Nutr (1998) 2.78
Immune responses to dietary antigens: oral tolerance. Immunol Today (1998) 2.04
Identification of an intestinal immune response using peripheral blood lymphocytes. Lancet (1988) 1.96
An evaluation of the taxonomy of Propionibacterium. Can J Microbiol (1968) 1.85
Polyarthritis in rats following the systemic injection of Lactobacillus casei cell walls in aqueous suspension. Arthritis Rheum (1983) 1.75
Endotoxin-mediated endothelial cell injury and activation: role of soluble CD14. Infect Immun (1993) 1.59
Lactic acid bacteria as vaccine delivery vehicles. Antonie Van Leeuwenhoek (1996) 1.51
Immune system stimulation by probiotics. J Dairy Sci (1995) 1.44
Potential of using lactic acid bacteria for therapy and immunomodulation in man. FEMS Microbiol Rev (1993) 1.42
Determination of complement-mediated killing of bacteria by viability staining and bioluminescence. Appl Environ Microbiol (1998) 1.20
Differential susceptibility to activation-induced apoptosis among peripheral Th1 subsets: correlation with Bcl-2 expression and consequences for AIDS pathogenesis. J Immunol (1998) 1.18
Adjuvanticity of lactobacilli. I. Differential effects of viable and killed bacteria. Clin Exp Immunol (1979) 1.15
Regulation of T cell subsets from naive to memory. J Immunother (1998) 0.99
Concanavalin A induced apoptosis in fibroblasts: the role of cell surface carbohydrates in lectin mediated cytotoxicity. J Cell Physiol (1995) 0.93
Effects of lactobacilli on parameters of non-specific resistance of mice. Med Microbiol Immunol (1981) 0.88
Immunomodulation by propionibacteria. Zentralbl Bakteriol (1990) 0.87
Immunomodulatory and protective effects of N-acetylcysteine in mitogen-activated murine splenocytes in vitro. Toxicology (1997) 0.83
Preoperative immunostimulation by Propionibacterium granulosum KP-45 in colorectal cancer. Anticancer Res (1994) 0.79
Con A cytotoxicity: a model for the study of key signaling steps leading to lymphocyte apoptosis in AIDS? Med Hypotheses (1995) 0.79
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med (2005) 17.06
The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med (2000) 8.46
Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr (2000) 4.08
Primary respiratory syncytial virus infection in mice. J Med Virol (1988) 3.77
Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest (1991) 3.71
Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness. J Immunol (1971) 3.33
Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis (1992) 3.07
Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines. Infect Immun (1982) 2.61
A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis (1994) 2.52
Canine kidney cell line for isolation of respiratory viruses. J Clin Microbiol (1979) 2.25
Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children < 5 years old. J Infect Dis (1997) 2.12
Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection. J Clin Microbiol (1986) 2.09
Comparison of competitive and indirect enzyme-linked immunosorbent assays for detection of bluetongue virus antibodies in serum and whole blood. J Clin Microbiol (1987) 2.07
Adhesion of some probiotic and dairy Lactobacillus strains to Caco-2 cell cultures. Int J Food Microbiol (1998) 1.98
Differing virulence of H1N1 and H3N2 influenza strains. Am J Epidemiol (1980) 1.97
Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis (1986) 1.97
Temperature-sensitive mutants of respiratory syncytial virus. J Virol (1969) 1.94
Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J (2001) 1.90
Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine. J Med Virol (1985) 1.88
Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis (1997) 1.86
The burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr (2000) 1.85
Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine-induced immunity. J Infect Dis (1994) 1.78
Adenovirus infections in young children. Pediatrics (1985) 1.76
Changing presentation of herpes simplex virus infection in neonates. J Infect Dis (1988) 1.76
Aberrant composition of gut microbiota of allergic infants: a target of bifidobacterial therapy at weaning? Gut (2002) 1.74
A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. J Infect Dis (1995) 1.68
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J Infect Dis (1993) 1.67
Cytomegalovirus pneumonia in two infants recently adopted from China. Clin Infect Dis (1999) 1.65
The natural history of human immunodeficiency virus 1 infection in Haitian infants. Pediatr Infect Dis J (1999) 1.64
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis (1998) 1.64
The ability of probiotic bacteria to bind to human intestinal mucus. FEMS Microbiol Lett (1998) 1.62
Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children. Infect Immun (1982) 1.61
Cold-adapted recombinant influenza A virus vaccines in seronegative young children. J Infect Dis (1982) 1.61
Development of subtype-specific and heterosubtypic antibodies to the influenza A virus hemagglutinin after primary infection in children. J Clin Microbiol (1985) 1.59
Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus. J Infect Dis (1988) 1.52
Twenty years of outpatient respiratory syncytial virus infection: a framework for vaccine efficacy trials. Pediatrics (1997) 1.51
Temperature-sensitive mutants of respiratory syncytial virus: in-vivo studies in hamsters. J Infect Dis (1970) 1.51
Comparison of influenza B/Hong Kong virus infections among infants, children, and young adults. J Infect Dis (1980) 1.47
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. J Infect Dis (1998) 1.47
Safety and antigenicity of influenza A/Hong Kong/68-ts-1 (E) (H3N2). J Pediatr (1975) 1.45
Candidate AIDS vaccines. N Engl J Med (1995) 1.41
Antibody-dependent cell-mediated cytotoxicity against influenza virus-infected cells. J Infect Dis (1983) 1.41
Reinfection of mice with respiratory syncytial virus. J Med Virol (1991) 1.39
Surface binding of aflatoxin B(1) by lactic acid bacteria. Appl Environ Microbiol (2001) 1.37
Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. Vaccine (1999) 1.37
Genetic studies of respiratory syncytial virus temperature-sensitive mutants. Arch Gesamte Virusforsch (1973) 1.36
A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. J Infect Dis (1995) 1.36
Influenza A infections in young children. Primary natural infection and protective efficacy of live-vaccine-induced or naturally acquired immunity. N Engl J Med (1977) 1.32
Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants. J Pediatr (1976) 1.31
Growth of influenza A virus in primary, differentiated epithelial cells derived from adenoids. J Virol (1996) 1.29
Trials of influenza A/New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity. J Infect Dis (1977) 1.26
Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network. J Infect Dis (1992) 1.25
Adherence of probiotic bacteria to human intestinal mucus in healthy infants and during rotavirus infection. Clin Diagn Lab Immunol (2001) 1.24
Serum immunoglobulin G antibody subclass responses to respiratory syncytial virus F and G glycoproteins after primary infection. J Clin Microbiol (1986) 1.22
Respiratory syncytial virus infection in anti-mu-treated mice. J Virol (1991) 1.20
Humoral and cellular immune responses of seronegative children vaccinated with a cold-adapted influenza A/HK/123/77 (H1N1) recombinant virus. Infect Immun (1980) 1.19
Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J Infect Dis (1996) 1.19
Chemical, physical and enzymatic pre-treatments of probiotic lactobacilli alter their adhesion to human intestinal mucus glycoproteins. Int J Food Microbiol (2000) 1.17
Electron microscopic studies of respiratory syncytial temperature-sensitive mutants. Arch Gesamte Virusforsch (1973) 1.16
Clinical studies of pneumococcal vaccines in infants. I. Reactogenicity and immunogenicity of two polyvalent polysaccharide vaccines. Rev Infect Dis (1981) 1.15
Secretory immunological response after intranasal inactivated influenza A virus vaccinations: evidence for immunoglobulin A memory. Infect Immun (1983) 1.14
Age-related response to two Haemophilus influenzae type b vaccines. J Pediatr (1982) 1.14
Immune correlates of protection against influenza in the human challenge model. Dev Biol (Basel) (2003) 1.13
Role of respiratory tract proteases in infectivity of influenza A virus. J Infect Dis (1987) 1.13
Evaluation of a temperature-sensitive mutant of respiratory syncytial virus in adults. J Infect Dis (1971) 1.12
Evaluation of the safety of amantadine-HC1 and the role of respiratory viral infections in children with cystic fibrosis. J Infect Dis (1976) 1.12
The effect of probiotic bacteria on the adhesion of pathogens to human intestinal mucus. FEMS Immunol Med Microbiol (1999) 1.11
A colorimetric microtiter plate PCR system detects respiratory syncytial virus in nasal aspirates and discriminates subtypes A and B. Diagn Microbiol Infect Dis (1999) 1.11
A comparison of five serological tests for bovine brucellosis. Can J Vet Res (1986) 1.10
Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine (2000) 1.07
Aprotinin and similar protease inhibitors as drugs against influenza. Antiviral Res (2011) 1.05
Application of a timing protocol to the reduction of inter-plate variability in the indirect enzyme immunoassay for detection of anti-Brucella antibody. J Immunoassay (1985) 1.04
The normal faecal microflora does not affect the adhesion of probiotic bacteria in vitro. FEMS Microbiol Lett (1999) 1.04
Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants. Vaccine (1999) 1.04
Characterizing the composition of intestinal microflora as a prospective treatment target in infant allergic disease. FEMS Immunol Med Microbiol (2001) 1.04
Lack of comparability between commonly used serological assays of immune response to Haemophilus influenzae vaccine. J Infect Dis (1987) 1.04
Eustachian tube histopathology during experimental influenza A virus infection in the chinchilla. Ann Otol Rhinol Laryngol (1987) 1.03
Human ileostomy glycoproteins as a model for small intestinal mucus to investigate adhesion of probiotics. Lett Appl Microbiol (1999) 1.03
Good adhesion properties of probiotics: a potential risk for bacteremia? FEMS Immunol Med Microbiol (2001) 1.03
An outbreak of airborne nosocomial varicella. Pediatrics (1982) 1.03
Ureaplasma urealyticum polyarthritis in agammaglobulinemia. Pediatr Infect Dis (1986) 1.02
Inhibition of Salmonella typhimurium adhesion to Caco-2 cell cultures by Lactobacillus strain GG spent culture supernate: only a pH effect? FEMS Immunol Med Microbiol (1997) 1.02
Development and evaluation of an indirect enzyme immunoassay for detection of porcine antibodies to pseudorabies virus. Can J Vet Res (1986) 1.01
Coumarin 7-hydroxylase activity in human liver microsomes. Properties of the enzyme and interspecies comparisons. Br J Clin Pharmacol (1985) 1.01
Evaluation of bivalent live attenuated influenza A vaccines in children 2 months to 3 years of age: safety, immunogenicity and dose-response. Vaccine (1997) 1.01
A review of enzyme immunoassay for detection of antibody to Brucella abortus in cattle. Vet Immunol Immunopathol (1988) 1.01
Management of genital herpes simplex virus infection occurring during pregnancy. Am J Obstet Gynecol (1981) 1.01
Clinical studies of pneumococcal vaccines in infants. II. Efficacy and effect on nasopharyngeal carriage. Rev Infect Dis (1981) 1.00
Clinical implications of preseptal (periorbital) cellulitis in childhood. Pediatrics (1978) 1.00
The effect of orally administered viable probiotic and dairy lactobacilli on mouse lymphocyte proliferation. FEMS Immunol Med Microbiol (1999) 0.99
Different virulence of influenza A virus strains and susceptibility to pneumococcal otitis media in chinchillas. Infect Immun (1983) 0.99
Antibody-dependent cell-mediated cytotoxicity against cells infected with respiratory syncytial virus: characterization of in vitro and in vivo properties. J Immunol (1979) 0.98
Complications of occult pneumococcal bacteremia in children. J Pediatr (1974) 0.98
The pharmacokinetics and efficacy of an aminoglycoside administered into the cerebral ventricles in neonates: implications for further evaluation of this route of therapy in meningitis. J Infect Dis (1981) 0.98
The influence of polyunsaturated fatty acids on probiotic growth and adhesion. FEMS Microbiol Lett (2001) 0.98
Optimization and standardization of an enzyme-linked immunosorbent assay protocol for serodiagnosis of Actinobacillus pleuropneumoniae serotype 5. J Clin Microbiol (1992) 0.97